@article {1819, title = {Evaluation of Antiviral Effects and Toxicity of Herbal Medicine Vipdervir Capsules}, journal = {Pharmacognosy Journal}, volume = {14}, year = {2022}, month = {June 2022}, pages = {681-689}, type = {Research Article}, chapter = {681}, abstract = {

Background: Antiviral vaccine is not effective, synthetic antiviral drugs are highly toxic, leading to increased interest in herbal medicines as promising antiviral drugs. Recently, Vipdervir has been developed from medicinal herbs with the aim to support and treat diseases caused by viruses such as H5N1 and SARSCoV- 2. In the present study, we assessed Vipdervir{\textquoteright}s antiviral activity against H5N1 and SARS-CoV-2. In addition, we also evaluated the acute toxicity and repeated dose toxicity of Vipdervir in mice and rabbits, respectively. Methods: H5N1 inhibitory effect of Vipdervir was assessed using hemagglutination inhibition assay. Vipdervir{\textquoteright}s SARS-CoV-2 inhibitory effect was evaluated by Plaque Reduction Neutralization assay. Acute and repeated dose oral toxicities of Vipdervir were determined according to OECD 423 and OECD 407 guidelines, respectively. Results: Data show that Vipdervir is effective against both H5N1 and SARSCoV- 2. At concentrations of 3 mg/mL and 5 mg/mL Vipdervir completely inhibits H5N1. At a concentration of 50 μg/mL Vipdervir showed an inhibitory effect on SARS-CoV-2. Acute toxicity data revealed that the LD50 of Vipdervir is greater than 35200 mg/kg, b.wt. in mice. Repeated toxicity data indicated that Vipdervir did not induce significant differences in body weight gain, hematology and clinical biochemistry in compared to the control group. The No Observed Adverse Effect Level of Vipdervir is greater than 613.8 mg/kg b.wt./day in rabbits. No delayed toxicity effects of Vipdervir were observed. Conclusion: Vipdervir capsules were found to be antiviral effective and relatively safe in the tested doses and experimental conditions.

}, keywords = {Antiviral, COVID-19, H5N1, Herbal, SARS-CoV-2.}, doi = {10.5530/pj.2022.14.87}, author = {Thi-Lien Nguyen and Huong Ha Thi Thanh and Kiet Ngo Tuan and Doan Cao Son and Thao Le Quang and Hang Nguyen Thi and Tien Vuong Duy and Quyen Doan Thi Tam and Huan Le Quang} } @article {1721, title = {Styrylpyrone Derivative from Goniothalamus sp.: A Powerful Drug for Fighting Against Herpes Simplex Virus Type 1}, journal = {Pharmacognosy Journal}, volume = {13}, year = {2021}, month = {December 2021}, pages = {1598-1606}, type = {Original Article}, chapter = {1598}, abstract = {

Background: The emergence of drug resistance towards Herpes Simplex Virus Type 1 (HSV-1) has encouraged scientists to develop novel lower toxicity and highly effective anti-HSV drugs. Styrylpyrone derivative (SPD) is a bioactive compound isolated from the roots and leaves of Goniothalamus sp. It is believed that this compound possesses antiviral properties against HSV-1. Objective: This paper introduces the interaction of SPD towards HSV-1 through in silico study of molecular docking and molecular dynamic simulation. Materials and Methods: Molecular docking is a computational tool which is used to study the molecular interaction between two or more structures. ADME/T properties of the SPD were generated using the SwissADME online tool in which SPD was found to have a good pharmacokinetic profile. Results: Molecular docking study revealed that SPD has a high docking score of -7.9 Kcal/mol. SPD has a strong affinity with the thymidine kinase (PDB id: 1OF1) producing hydrogen bond and non-polar interaction at the target point of amino acid residue. Conclusion: Molecular docking analysis provides new insight into the structure-based design of SPD compounds with better antiviral activity against HSV-1.

}, keywords = {Antiviral, Herpes Virus type 1 (HSV-1), in silico approaches, Molecular docking and Styrylpyrone derivative.}, doi = {10.5530/pj.2021.13.206}, author = {Syaza Safia Fouzi and Noor Zarina Abd Wahab and Leong Chee Yan and Nazlina Ibrahim} } @article {1188, title = {Drug of Action Cassia Alata Leaves Extract as Antiviral to Dengue Virus Serotype-2 in vitro}, journal = {Pharmacognosy Journal}, volume = {12}, year = {2020}, month = {June 2020}, pages = {864-871}, type = {Research Article}, chapter = {864}, abstract = {

Background and Objectives: Dengue viruses (DENV) is a mosquito-borne members of the Flaviridae family.To date, more than 2.5 billion people in over 100 countries are at risk of infection, and approximately 20 million infections were reported annually. Currently, There is no specific antiviral treatment available for DENV infection. Natural products possess a wide range of biological and biochemical potential. Among them, plants are one of the most important sources for discovering new drugs for therapy. Our previous study, showed that Cassia alata has potency as antiviral to DENV, however drug of action still unclear. Materials and Methods: We explore the drug of action of C. alata leaves exract and its fraction through time of addition studies and effect of solvents wtih the dose based on the previous study. Results: The most effective inhibition druf of action was determined by focus assay. Meanwhile the toxicity was measured by MTT assay. These studies demosntrated that ethanol extract of Cassia alata 1 mg/ml showed strong inhibition in both early step (receptor and attachment to host cells) and post infection with inhibition 96.04 \% and 99.16 \%.Compared with those fractions, Cassia alata ethanol extract has strongest inhibition DENV in every step of virus replication. Conclussion: Cassia alata ethanol extract has strongest inhibition DENV in every step of virus replication with the average of inhibition more than 95 \%. Ethyl acetate and hexane has strongest inihibition with the average of inhibition 100 \%.

}, keywords = {Antiviral, Cassia alata, Dengue virus, Early step, Post infection}, doi = {10.5530/pj.2020.12.124}, author = {Marissa Angelina and Muhammad Hanafi and Franciscus D Suyatna and Beti Ernawati Dewi} } @article {470, title = {Evaluation of in vitro Antiviral Activity of Essential Oil Compounds Against Dengue Virus}, journal = {Pharmacognosy Journal}, volume = {10}, year = {2018}, month = {December 2017}, pages = {55-59}, type = {Original Article}, chapter = {55}, abstract = {

Introduction: There are not effective drugs available for treatment of dengue fever despite intensive research on synthetic inhibitors. The search for active phytochemicals could serve for the discovery of new drugs. This study aims to evaluate the antiviral activity in vitro of compounds found in essential oils from medicinal plants. Materials and Methods: Nine synthetic-derived essential oil compounds were evaluated. Antiviral effect was screened measuring the reduction of viral NS1 and E proteins in HepG-2 and Vero cells. Results: \β-Caryophyllene was identified as the most active compound, it reduced the virus serotype-2 replication in HepG-2 cells at IC50 of 22 \± 5.6 \μM, and blocked replication of all four serotypes in Vero cells at IC50 between 8.0 \μM and 15.0 \μM. The selectivity indexes were between 5.3 and 10. According to results from time-in-addition assays, the antiviral effect of \β-caryophyllene appears to be associated with interruption of early steps of the virus life cycle. Citral revealed modest antiviral effect, it reduced the virus serotype-2 (IC50 of 31 \± 4.5 \μM) replication but not the other three serotypes. Seven terpenes did not reveal antiviral activity at maximum concentration of 30 \μM. Conclusion: Research on compounds found in essential oils can contribute to the drug discovery effort for dengue. \β-Caryophyllene could serve as a starting point.

}, keywords = {Antiviral, Dengue, Essential oil, Flavivirus, Terpene}, doi = {10.5530/pj.2018.1.11}, url = {http://fulltxt.org/article/366}, author = {Mar{\'\i}a C. Flechas and Raquel E. Ocazionez and Elena E. Stashenko} }